Sign up to save your podcasts
Or
Share The Beacon
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Beacon
The Beacon episodes
- Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients.
3 min - Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other treatment options in this setting.
3 min - Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for the future role of immunotherapy in RCC.
4 min - Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic disease in patients with renal cell carcinoma (RCC).
3 min - Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in metastatic renal cell carcinoma (RCC), providing insight into how the data should be applied in clinical practice.
5 min - Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting fibroblast growth factor receptor (FGFR) alterations in muscle-invasive, advanced bladder cancer.
4 min - Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced transitional cell carcinoma of the bladder.
3 min - Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising questions of utility in pancreatic cancer.
2 min - Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?
4 min - How do Patients with Advanced NSCLC on Daily Steroids Do on Immune Checkpoint Inhibitors? (BMIC-046)
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients with advanced NSCLC on daily steroids while receiving an immune checkpoint inhibitor against PD-1 or PD-L1.
10 min
About The Beacon
From the publisher's feed
Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.